Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage

BMC Medical Genomics

Volumn 6, Issue 1, 2013, Pages

  De Schutter, Tim ^a   Andrei, Graciela ^a   Topalis, Dimitri ^a   Naesens, Lieve ^a   Snoeck, Robert ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Cervical carcinoma; Cidofovir; DNA damage and repair; Gene expression profiling; Human papillomavirus

Indexed keywords

ALCOHOL OXIDASE; ALDEHYDE OXIDASE; CELL DNA; CIDOFOVIR; GENOMIC DNA; HISTONE; LIVER X RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; ONCOSTATIN M RECEPTOR; OXIDOREDUCTASE; PROTEIN E6; PROTEIN E7; RETINOID X RECEPTOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ALDEHYDE OXIDASE 1 GENE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL IMMORTALIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEHYDROGENASE REDUCTASE SDR FAMILY MEMBER 2 GENE; DNA DAMAGE; DNA REPAIR; DRUG DISTRIBUTION; DRUG EFFECT; DRUG METABOLISM; DRUG SCREENING; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC STABILITY; GENOMIC INSTABILITY; HISTONE CLUSTER 1 GENE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; ICAM4 GENE; KERATINOCYTE; MICROARRAY ANALYSIS; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6 GENE; NUCLEOTIDE SEQUENCE; ONCOSTATIN M RECEPTOR GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL RATE; UTERINE CERVIX CARCINOMA; WART VIRUS;

ANTIVIRAL AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE; COMPUTATIONAL BIOLOGY; CYTOSINE; DNA DAMAGE; DNA REPAIR; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HELA CELLS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOPHOSPHONATES; PAPILLOMAVIRIDAE; RETINOID X RECEPTORS; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; UP-REGULATION;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84878005004     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-6-18     Document Type: Article

References (70)

1. Epidemiology of human papillomavirus infection and associations with cervical cancer: new opportunities for prevention. Bosch FX, de Sanjosé S, Castellsague X, Moreno V, Muñoz N, Papillomavirus Research: From Natural History to Vaccines and Beyond UK: Caister Academic Press, Campo MS, 2006 19 40
2. Molecular biology of human papillomavirus infection and cervical cancer. Doorbar J, Clin Sci (Lond) 2006 110 525 541
3. Papillomaviruses and cancer: from basic studies to clinical application. zur Hausen H, Nat Rev Cancer 2002 2 342 350 10.1038/nrc798 12044010
4. A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Ziegert C, Wentzensen N, Vinokurova S, Kisseljov F, Einenkel J, Hoeckel M, et al. Oncogene 2003 22 3977 3984 10.1038/sj.onc.1206629 12813471
5. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM, J Virol 1987 61 962 971 3029430
6. Persistence of human papillomavirus infection: keys to malignant progression. Bodily J, Laimins LA, Trends Microbiol 2011 19 33 39 10.1016/j.tim.2010.10.002 21050765
7. Human papillomavirus oncoproteins: pathways to transformation. Moody CA, Laimins LA, Nat Rev Cancer 2010 10 550 560 10.1038/nrc2886 20592731
8. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, et al. Oncogene 2001 20 7888 7898 10.1038/sj.onc.1204860 11753671
9. Papillomavirus E6 proteins. Howie HL, Katzenellenbogen RA, Galloway DA, Virology 2009 384 324 334 10.1016/j.virol.2008.11.017 19081593
10. Acyclic nucleoside phosphonates: a key class of antiviral drugs. De Clercq E, Holy A, Nat Rev Drug Discov 2005 4 928 940 10.1038/nrd1877 16264436
11. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Van Pachterbeke C, Bucella D, Rozenberg S, Manigart Y, Gilles C, Larsimont D, et al. Gynecol Oncol 2009 115 69 74 10.1016/j.ygyno.2009.06.042 19647859
12. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M, J Med Virol 2000 60 205 209 10.1002/(SICI)1096-9071(200002)60:2<205::AID- JMV16>3.0.CO;2-8
13. Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir. Koonsaeng S, Verschraegen C, Freedman R, Bossens M, Kudelka A, Kavanagh J, et al. J Med Virol 2001 64 195 198 10.1002/jmv.1036 11360253
14. Safety and efficacy of topical Cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. Stier EA, Goldstone SE, Einstein MH, Jay N, Berry JM, Wilkin T, et al. AIDS 2013 27 545 551 10.1097/QAD.0b013e32835a9b16 23032420
15. Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. Tristram A, Fiander A, Gynecol Oncol 2005 99 652 655 10.1016/j.ygyno.2005.07.127 16169066
16. Novel treatment of atypical human papillomavirus-associated epithelial hyperplasia with cidofovir. Collette DC, Zechel MA, J Oral Maxillofac Surg 2011 69 2383 2386 10.1016/j.joms.2010.10.040 21292369
17. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. Van Cutsem E, Snoeck R, Van Ranst M, Fiten P, Opdenakker G, Geboes K, et al. J Med Virol 1995 45 230 235 10.1002/jmv.1890450221 7775945
18. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E, Oncol Res 1998 10 523 531 10338155
19. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Andrei G, Snoeck R, Schols D, De Clercq E, Oncol Res 2000 12 397 408 11697818
20. Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro. Hostetler KY, Rought S, Aldern KA, Trahan J, Beadle JR, Corbeil J, Mol Cancer Ther 2006 5 156 159 16432174
21. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Abdulkarim B, Sabri S, Deutsch E, Chagraoui H, Maggiorella L, Thierry J, et al. Oncogene 2002 21 2334 2346 10.1038/sj.onc.1205006 11948417
22. Antiviral activity of Cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Sirianni N, Wang J, Ferris RL, Oral Oncol 2005 41 423 428 10.1016/j.oraloncology.2004.11.003 15792615
23. Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells. Amine A, Rivera S, Opolon P, Dekkal M, Biard DS, Bouamar H, et al. PLoS One 2009 4 5018 10.1371/journal.pone.0005018 19325708
24. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Johnson JA, Gangemi JD, Antimicrob Agents Chemother 1999 43 1198 1205 10223936
25. Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis. Oliva J, French SW, Li J, Bardag-Gorce F, Exp Mol Pathol 2012 93 26 34 10.1016/j.yexmp.2012.03.006 22445925
26. Gene expression profiling and pathway network analysis of hepatic metabolic enzymes targeted by baicalein. Qin S, Chen J, Tanigawa S, Hou DX, J Ethnopharmacol 2012 140 131 140 10.1016/j.jep.2011.12.046 22265932
27. Organotypic epithelial raft cultures as a model for evaluating compounds against alphaherpesviruses. Andrei G, van den Oord J, Fiten P, Opdenakker G, De Wolf-Peeters C, De Clercq E, et al. Antimicrob Agents Chemother 2005 49 4671 4680 10.1128/AAC.49.11.4671-4680.2005 16251311
28. Summaries of Affymetrix GeneChip probe level data. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP, Nucleic Acids Res 2003 31 15 10.1093/nar/gng015 12582260
29. Controlling the false discovery rate-a practical and powerful approach to multiple testing. Benjamini Y, Hochberg Y, J Roy Stat Soc B Met 1995 57 289 300
30. Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine. Naesens L, Andrei G, Votruba I, Krecmerova M, Holy A, Neyts J, et al. Biochem Pharmacol 2008 76 997 1005 10.1016/j.bcp.2008.08.009 18773877
31. The retinoid X receptors and their ligands. Dawson MI, Xia Z, Biochim Biophys Acta 1821 2012 21 56
32. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB, Cell Metab 2008 7 11 20 10.1016/j.cmet.2007.10.002 18177721
33. Playing the end game: DNA double-strand break repair pathway choice. Chapman JR, Taylor MR, Boulton SJ, Mol Cell 2012 47 497 510 10.1016/j.molcel. 2012.07.029 22920291
34. Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy. Aziz K, Nowsheen S, Pantelias G, Iliakis G, Gorgoulis VG, Georgakilas AG, Pharmacol Ther 2012 133 334 350 10.1016/j.pharmthera.2011. 11.010 22197993
35. Irreversible G2-M arrest and cytoskeletal reorganization induced by cytotoxic nucleoside analogues. Halloran PJ, Fenton RG, Cancer Res 1998 58 3855 3865 9731495
36. S- and G2-phase cell cycle arrests and apoptosis induced by ganciclovir in murine melanoma cells transduced with herpes simplex virus thymidine kinase. Wei SJ, Chao Y, Hung YM, Lin WC, Yang DM, Shih YL, et al. Exp Cell Res 1998 241 66 75 10.1006/excr.1998.4005 9633514
37. Cidofovir induces an increase in levels of low-risk and high-risk HPV E6. Donne AJ, Hampson L, He XT, Rothera MP, Homer JJ, Hampson IN, Head Neck 2009 31 893 901 10.1002/hed.21043 19283851
38. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. Kelley ML, Keiger KE, Lee CJ, Huibregtse JM, J Virol 2005 79 3737 3747 10.1128/JVI.79.6.3737-3747.2005 15731267
39. Control of interferon signaling in human papillomavirus infection. Koromilas AE, Li S, Matlashewski G, Cytokine Growth Factor Rev 2001 12 157 170 10.1016/S1359-6101(00)00023-X 11325599
40. Preferential nuclear localization of the human papillomavirus type 16 E6 oncoprotein in cervical carcinoma cells. Masson M, Hindelang C, Sibler AP, Schwalbach G, Trave G, Weiss E, J Gen Virol 2003 84 2099 2104 10.1099/vir.0.18961-0 12867640
41. Gamma interferon-inducible protein 10 induces HeLa cell apoptosis through a p53-dependent pathway initiated by suppression of human papillomavirus type 18 E6 and E7 expression. Zhang HM, Yuan J, Cheung P, Chau D, Wong BW, McManus BM, et al. Mol Cell Biol 2005 25 6247 6258 10.1128/MCB.25.14.6247-6258.2005 15988033
42. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Henley SA, Dick FA, Cell Div 2012 7 10 10.1186/1747-1028-7-10 22417103
43. Regulation of the p53 tumor suppressor protein. Oren M, J Biol Chem 1999 274 36031 36034 10.1074/jbc.274.51.36031 10593882
44. The MDM2-p53 interaction. Moll UM, Petrenko O, Mol Cancer Res 2003 1 1001 1008 14707283
45. The regulation of the p53-mediated stress response by MDM2 and MDM4. Perry ME, Cold Spring Harb Perspect Biol 2010 2 000968 10.1101/cshperspect. a000968 20182601
46. Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells. Real PJ, Sanz C, Gutierrez O, Pipaon C, Zubiaga AM, Fernandez-Luna JL, FEBS Lett 2006 580 5905 5909 10.1016/j.febslet.2006.08.088 17027756
47. BIK, the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes. Chinnadurai G, Vijayalingam S, Rashmi R, Oncogene 2008 27 Suppl 1 20 S29 19641504
48. Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-kappaB survival signaling in lung cancer cells. Deng LL, Shao YX, Lv HF, Deng HB, Lv FZ, Neoplasma 2012 59 18 29 10.4149/neo-2012-003 22017589
49. Overexpression of Dickkopf-3 induces apoptosis through mitochondrial pathway in human colon cancer. Yang ZR, Dong WG, Lei XF, Liu M, Liu QS, World J Gastroenterol 2012 18 1590 1601 10.3748/wjg.v18.i14.1590 22529687
50. Macrophage inhibitory cytokine-1 (MIC-1) and subsequent urokinase-type plasminogen activator mediate cell death responses by ribotoxic anisomycin in HCT-116 colon cancer cells. Yang H, Choi HJ, Park SH, Kim JS, Moon Y, Biochem Pharmacol 2009 78 1205 1213 10.1016/j.bcp.2009.06.012 19540205
51. TIMP-3 promotes apoptosis in nonadherent small cell lung carcinoma cells lacking functional death receptor pathway. Kallio JP, Hopkins-Donaldson S, Baker AH, Kahari VM, Int J Cancer 2011 128 991 996 10.1002/ijc.25404 20473894
52. mRTVP-1, a novel p53 target gene with proapoptotic activities. Ren C, Li L, Goltsov AA, Timme TL, Tahir SA, Wang J, et al. Mol Cell Biol 2002 22 3345 3357 10.1128/MCB.22.10.3345-3357.2002 11971968
53. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Li L, Ren C, Yang G, Fattah EA, Goltsov AA, Kim SM, et al. Cancer Res 2011 71 7694 7704 10.1158/0008-5472.CAN-11-1714 22025562
54. L-Maf regulates p27kip1 expression during chick lens fiber differentiation. Reza HM, Nishi H, Kataoka K, Takahashi Y, Yasuda K, Differentiation 2007 75 737 744 10.1111/j.1432-0436.2007.00171.x 17428264
55. c-Maf induces monocytic differentiation and apoptosis in bipotent myeloid progenitors. Hegde SP, Zhao J, Ashmun RA, Shapiro LH, Blood 1999 94 1578 1589 10477683
56. c-Maf interacts with c-Myb to down-regulate Bcl-2 expression and increase apoptosis in peripheral CD4 cells. Peng S, Lalani S, Leavenworth JW, Ho IC, Pauza ME, Eur J Immunol 2007 37 2868 2880 10.1002/eji.200636979 17823980
57. Maf transcriptionally activates the mouse p53 promoter and causes a p53-dependent cell death. Hale TK, Myers C, Maitra R, Kolzau T, Nishizawa M, Braithwaite AW, J Biol Chem 2000 275 17991 17999 10.1074/jbc.M000921200 10747965
58. Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno B, Raschella G, et al. Oncotarget 2010 1 278 288 21304178
59. A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Sottile F, Gnemmi I, Cantilena S, D'Acunto WC, Sala A, Oncotarget 2012 3 535 545 22619121
60. The MYCN oncoprotein as a drug development target. Lu X, Pearson A, Lunec J, Cancer Lett 2003 197 125 130 10.1016/S0304-3835(03)00096-X 12880971
61. The microRNA-17-92 cluster: still a miRacle? Bonauer A, Dimmeler S, Cell Cycle 2009 8 3866 3873 10.4161/cc.8.23.9994 19887902
62. Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma. De Brouwer S, Mestdagh P, Lambertz I, Pattyn F, De PA, Westermann F, et al. Int J Cancer 2012 130 2591 2598 10.1002/ijc.26295 21796614
63. Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression. Frenzel A, Zirath H, Vita M, Albihn A, Henriksson MA, PLoS One 2011 6 27988 10.1371/journal.pone.0027988 22132187
64. Acute-phase proteins and other systemic responses to inflammation. Gabay C, Kushner I, N Engl J Med 1999 340 448 454 10.1056/NEJM199902113400607 9971870
65. DNA damage checkpoints in stem cells, ageing and cancer. Sperka T, Wang J, Rudolph KL, Nat Rev Mol Cell Biol 2012 13 579 590 10.1038/nrm3420 22914294
66. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Jakobsson T, Treuter E, Gustafsson JA, Steffensen KR, Trends Pharmacol Sci 2012 33 394 404 10.1016/j.tips.2012.03.013 22541735
67. LXR agonists and ABCG1-dependent cholesterol efflux in MCF-7 breast cancer cells: relation to proliferation and apoptosis. El Roz A, Bard JM, Huvelin JM, Nazih H, Anticancer Res 2012 32 3007 3013 22753765
68. Role of Rho GTPases and their regulators in cancer progression. Rathinam R, Berrier A, Alahari SK, Front Biosci 2011 16 2561 2571 10.2741/3872 21622195
69. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Zhang B, Zhang Y, Dagher MC, Shacter E, Cancer Res 2005 65 6054 6062 10.1158/0008-5472.CAN-05-0175 16024605
70. Guanine nucleotide exchange factors for RhoGTPases: good therapeutic targets for cancer therapy? Lazer G, Katzav S, Cell Signal 2011 23 969 979 10.1016/j.cellsig.2010.10.022 21044680